Topical prostaglandin analogues do not affect selective laser trabeculoplasty outcomes

Eye

Volumn 23, Issue 12, 2009, Pages 2194-2199

  Singh, D ^a   Coote, M A ^a,b   O'Hare, F ^a   Walland, M J ^b   Ghosh, S ^a,b   Xie, J ^a   Ruddle, J B ^a,b   Crowston, J G ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

Glaucoma; Intraocular pressure; Prostaglandin analogues; Selective laser trabeculoplasty

Indexed keywords

BIMATOPROST; LATANOPROST; TRAVOPROST;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; RISK FACTOR; TRABECULOPLASTY;

ADMINISTRATION, TOPICAL; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; KAPLAN-MEIER ESTIMATE; LASER THERAPY; LOGISTIC MODELS; OUTCOME ASSESSMENT (HEALTH CARE); PROSTAGLANDINS; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; RISK FACTORS; TRABECULAR MESHWORK; TRABECULECTOMY;

EID: 72749111172     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.1     Document Type: Article

References (20)

1. Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology 1998; 105: 2082-2088; discussion 2089-2090.
2. Damji KF, Bovell AM, Hodge WG, Rock W, Shah K, Buhrmann R et al. Selective laser trabeculoplasty vs argon laser trabeculoplasty: results from a 1-year randomised clinical trial. Br J Ophthalmol 2006; 90: 1490-1494.
3. Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, Matilla M, Macias JM, Benitez-del-Castillo JM et al. Selective vs argon laser trabeculoplasty: hypotensive efficacy, anterior chamber inflammation, and postoperative pain. Eye 2004; 18: 498-502.
4. Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology 2001; 108: 773-779.
5. Hodge WG, Damji KF, Rock W, Buhrmann R, Bovell AM, Pan Y. Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. Br J Ophthalmol 2005; 89: 1157-1160.
6. Francis BA, Ianchulev T, Schofield JK, Minckler DS. Selective laser trabeculoplasty as a replacement for medical therapy in open-angle glaucoma. Am J Ophthalmol 2005; 140: 524-525.
7. Johnson PB, Katz LJ, Rhee DJ. Selective laser trabeculoplasty: predictive value of early intraocular pressure measurements for success at 3 months. Br J Ophthalmol 2006; 90: 741-743.
8. Juzych MS, Chopra V, Banitt MR, Hughes BA, Kim C, Goulas MT et al. Comparison of long-term outcomes of selective laser trabeculoplasty vs argon laser trabeculoplasty in open-angle glaucoma. Ophthalmology 2004; 111: 1853-1859.
9. McIlraith I, Strasfeld M, Colev G, Hutnik CM. Selective laser trabeculoplasty as initial and adjunctive treatment for openangle glaucoma. J Glaucoma 2006; 15: 124-130.
10. Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study. Arch Ophthalmol 2003; 121: 957-960.
11. Nagar M, Ogunyomade A, O'Brart DP, Howes F, Marshall J. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol 2005; 89: 1413-1417.
12. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996; 103: 1916-1924.
13. Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002; 120: 1286-1293.
14. Scherer WJ. Effect of topical prostaglandin analog use on outcome following selective laser trabeculoplasty. J Ocul Pharmacol Ther 2007; 23: 503-512.
15. Song J, Lee PP, Epstein DL, Stinnett SS, Herndon Jr LW, Asrani SG et al. High failure rate associated with 180 degrees selective laser trabeculoplasty. J Glaucoma 2005; 14: 400-408.
16. Gracner T. Intraocular pressure response to selective laser trabeculoplasty in the treatment of primary open-angle glaucoma. Ophthalmologica 2001; 215: 267-270. (Pubitemid 32588884)
17. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-440.
18. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-1279.
19. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-713; discussion 829-1730
20. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-1953.